Handgrip Strength and Sarcopenic Obesity

Almost everything written about muscle and these drugs measures mass on a scan. The SEMALEAN study measured something better: what people could actually do. Over twelve months on semaglutide 2.4 mg, handgrip strength improved by 4.5 kg, and the prevalence of sarcopenic obesity fell from 49% to 33%.^[1]

What happened, in order

Fat mass fell 18% by month twelve. Lean mass declined by about 3 kg by month seven — and then stabilized rather than continuing down.^[1]

The lean-mass loss is front-loaded, and then it stops. It is not a slope that continues for as long as you take the drug.

That shape matters for the argument people actually have. “These drugs eat your muscle” implies an ongoing process. What this describes is an early adjustment as body size falls, followed by a plateau — which is what you would expect if lean loss is a consequence of needing less muscle to move a smaller body.

The functional results

• Handgrip strength rose 4.5 kg by month twelve. Grip strength is a standard, hard-to-fake proxy for whole-body strength and a well-validated predictor of outcomes.
• Sarcopenic obesity fell from 49% to 33% — a formal diagnosis, resolving in a third of those who had it.
• Resting energy expenditure normalized to lean mass rose between months seven and twelve, meaning the remaining tissue was not becoming metabolically sluggish.

This is consistent with a smaller study we covered in muscle volume versus muscle function, where psoas volume fell 9.3% while chair-rise time and walking speed both improved slightly. Two independent studies finding mass down and function up is a more useful pattern than either alone.

Who responded differently

Three subgroup findings are worth knowing, and one is directly practical.

1. Women lost more weight and fat mass, consistent with the randomized picture in who loses more weight.
2. People with type 2 diabetes, or prior GLP-1 use, showed attenuated responses. The diabetes finding is well established. The prior-use one matters for anyone switching drugs — see switching.
3. People with a history of bariatric surgery showed the most pronounced changes, which is relevant to the growing group taking these drugs after weight regain following surgery.

The prior-GLP-1 finding deserves particular attention because it is rarely mentioned. If you have taken one of these drugs before, the response to the next may be smaller than the trial figures suggest — and trial populations are typically drug-naive.